Press Release Archive
-
Janssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant TuberculosisJanssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
-
Johnson & Johnson to Participate in Barclays Global Consumer Staples ConferenceJohnson & Johnson to Participate in Barclays Global Consumer Staples Conference
-
Johnson & Johnson to Participate in the Wells Fargo Securities 2019 Healthcare ConferenceJohnson & Johnson to Participate in the Wells Fargo Securities 2019 Healthcare Conference
-
Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosisJanssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis
-
Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine RegimenJohnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen
-
Johnson & Johnson Establishes International Consortium to Advance Pioneering Science in the Fight to End TuberculosisJohnson & Johnson Establishes International Consortium to Advance Pioneering Science in the Fight to End Tuberculosis
-
Johnson & Johnson Reports 2019 Second-Quarter Results:Johnson & Johnson Reports 2019 Second-Quarter Results:
-
Johnson & Johnson Extends Long-Standing Donation Program to Support Global Effort to Tackle Intestinal WormsJohnson & Johnson Extends Long-Standing Donation Program to Support Global Effort to Tackle Intestinal Worms
-
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2019Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2019
-
Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV VaccineJohnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine